The United States research and development (R&D) ecosystem has historically been supported by a policy and regulatory framework that has led to unprecedented levels of collaboration and innovation. In 2021 alone, brand name biopharmaceutical companies invested over $100 billion into R&D and there are more than 8,000 medicines in development today. Much of this success can be attributed to the Bayh-Dole Act.
Formally known as the University and Small Business Patent Procedures Act, when passed by Congress in 1980 the Bayh-Dole Act fundamentally changed how federally funded research gets turned into commercialized products. Prior to its passage, inventions arising from government-funded research often languished in bureaucratic red tape, rarely seeing the light of day. However, Bayh-Dole's groundbreaking provisions allowed researchers receiving federal funds to patent their inventions and license them to private companies so they could continue to research and develop them into products that benefit the public.
Without the Bayh-Dole Act, and significant investments from the private sector, any knowledge gained through government-supported research would generate interesting ideas but very few new products. Before Bayh-Dole, not a single drug built on government-funded research had been further developed. Since the legislation’s passage more than 40 years ago, over 200 new medications and vaccines have been created through these partnerships. Further, this collaboration has contributed nearly $2 trillion to our economy and supported 6.5 million jobs.
Thanks to public-private collaboration and licensing, we've witnessed the development of groundbreaking treatments and cures for conditions such as cancer, rare diseases and infectious diseases.
The Bayh-Dole Act has been an invaluable catalyst for biopharmaceutical innovation. By empowering academic institutions and industry to take ownership of their research, fostering collaboration, and streamlining the process of bringing discoveries to market, this legislation has played a central role in shaping the biopharmaceutical landscape we know today.
Learn more about Bayh-Dole here.
Jocelyn Ulrich
Jocelyn Ulrich, MPH, is Vice President of Policy and Research at the Pharmaceutical Research and Manufacturers of America (PhRMA). At PhRMA, she is responsible for developing legislative and policy analysis and research studies on a range of issues impacting innovative biopharmaceutical companies including intellectual property issues, FDA policy issues, the R&D process, the value of innovation, and other issue areas impacting the environment for innovation. In addition to her experience at PhRMA she has over 15 years of experience in the pharmaceutical industry at Pfizer, Human Genome Sciences, and EMD Serono in roles in clinical research management, investigator-initiated and collaborative research, and global policy and corporate affairs. Jocelyn holds an MPH in global health policy and management from New York University.
Jocelyn Ulrich
Bayh-Dole: The fuel for America’s innovation engine
ICYMI: Biopharmaceutical companies in America hit new investment milestone
Setting the record straight: 3 facts about drug patents
New PBM principles don't change the fundamental challenge: Access to lower-cost medicines
Word of the Month: The Bayh-Dole Act
Intellectual Property
Research and Development
Word of the Month
Word of the Month: The Bayh-Dole Act
Word of the Month: The Bayh-Dole Act